Adiponectin and its role in the obesity-induced insulin resistance and related complications
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
15046547
Knihovny.cz E-resources
- MeSH
- Adiponectin MeSH
- Arteriosclerosis drug therapy etiology MeSH
- Diabetes Mellitus metabolism physiopathology MeSH
- Insulin Resistance physiology MeSH
- Blood Glucose drug effects MeSH
- Humans MeSH
- Intercellular Signaling Peptides and Proteins genetics physiology therapeutic use MeSH
- Mice, Knockout MeSH
- Mice MeSH
- Obesity complications metabolism physiopathology MeSH
- Gene Expression Regulation physiology MeSH
- Adipose Tissue metabolism physiology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Adiponectin MeSH
- Blood Glucose MeSH
- Intercellular Signaling Peptides and Proteins MeSH
It is now generally accepted that adipose tissue acts as an endocrine organ producing a number of substances with an important role in the regulation of food intake, energy expenditure and a series of metabolic processes. Adiponectin is a recently discovered protein produced exclusively by adipocytes. A number of studies have shown that obesity, insulin resistance and atherosclerosis are accompanied by decreased adiponectin levels and that adiponectin replacement under experimental settings is able to diminish both insulin resistance and atherosclerosis. The aim of this review is to summarize the current knowledge about the physiology and pathophysiology of adiponectin and to discuss its potential in the treatment of insulin resistance and atherosclerosis.
